Stephens Consulting’s Roivant Sciences ROIV Stock Holding History

Stephens Consulting’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3	Closed	-$34	–	1001
2025 Q2	$34	Buy	+3	New	+$33	﹤0.01%	1145

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Stephens Consulting's ROIV Position: Q3 2025 in Review

Stephens Consulting sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 3 shares — an estimated $34 sold.

Stephens Consulting first reported a position in ROIV in Q2 2025 and held it in 1 quarter. The position peaked at $34 in Q2 2025. 337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

Stephens Consulting reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
Stephens Consulting sold 3 Roivant Sciences shares in Q3 2025, an estimated $34.
Stephens Consulting first reported a position in Roivant Sciences in Q2 2025 and held it in 1 quarter.
Stephens Consulting's Roivant Sciences position peaked at $34 in Q2 2025.
337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.